In terms of controlling what they can control, I believe Alnylam Pharmaceuticals ( ALNY ) management is doing a good job. While there has certainly been criticism of the high cash burn and the large sums that the company spends on R&D, I believe funding a robust Phase III development pro...

You only have to do very few things right in your life so long as you don't do too many things wrong. - Warren Buffett Though successful innovation entails mega-profits, the field is fraught with risks. Therefore, a bioscience theme that I like is when a company genuinely admits failure an...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company and its collaborators will present at the 2019 International Congress on Porphyrins and Porphyria (ICPP), being held September 8-11, 2019 in Milan, Italy. Presentations will...